NCT05834751 is a NA clinical trial of PEG-rhG-CSF in Lymphoma, sponsored by Ou Bai, MD/PHD.

Who is sponsoring NCT05834751?

NCT05834751 is sponsored by Ou Bai, MD/PHD.

What drugs are being tested in NCT05834751?

Interventions in NCT05834751: PEG-rhG-CSF, RhG-CSF.

Is NCT05834751 still recruiting?

NCT05834751 is currently status unknown. Last updated 28 April 2023.

Last reviewed 2023-04-28 · How we verify

NCT05834751

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma

Status unknown NA Last updated 28 April 2023

What this trial tests

NA trial testing PEG-rhG-CSF in Lymphoma in 144 participants. Status unknown.

Timeline

1 May 2023

Primary endpoint
1 May 2025

1 July 2025

Quick facts

Lead sponsor	Ou Bai, MD/PHD
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	144
Start date	1 May 2023
Primary completion	1 May 2025
Estimated completion	1 July 2025
Sites	1 location across China

Drugs / interventions tested

PEG-rhG-CSF — full drug profile →
RhG-CSF — full drug profile →

Conditions studied

Lymphoma — all drugs for Lymphoma →

Sponsor

Ou Bai, MD/PHD

Who can join

Adults 18 to 65, any sex, with Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A single center, non-inferiority, two-way cohort clinical study to evaluate the efficacy and safety of pegylated recombinant human granulocyte stimulating factor injection in the mobilization of autologous hematopoietic stem cells in lymphoma.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Polyethylene glycol-conjugated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) primary prophylaxis significantly reduces the duration of neutropenia in non-Hodgkin's lymphoma patients treated with chemotherapy: a randomised trial (NCT05834751).
Wang B, Cao L, Li J, Zhao Y, et al · · 2025 · PMID 41510127 · DOI 10.21037/tcr-2025-1-2613

Verify or expand the search:

Other trials of PEG-rhG-CSF

Trials testing the same drug.

NCT05970185 — The Value of Peripheral Blood CD34+ Cell Dynamics Monitoring in Autologous Hematopoietic Stem Cell Transplant Mobilizati · EARLY_PHASE1 · unknown
NCT05510089 — Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies · NA · unknown
NCT05409547 — A Clinical Study of Autologous Peripheral Blood Stem Cell Mobilization for PEG-G-CSF · Phase 4 · unknown
NCT05531279 — A Study of PEG-rhG-CSF and rhG-CSF Used for Aplastic Anemia Granulocyte Deficiency · NA · unknown
NCT06026995 — Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells · Phase 4 · unknown

Other recruiting trials for Lymphoma

Currently open trials in the same condition.

NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers · NA · recruiting
NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma · Phase 1, PHASE2 · recruiting

Other Ou Bai, MD/PHD trials

Trials by the same sponsor.

NCT07493109 — Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP · Phase 3 · recruiting
NCT07493148 — Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL · Phase 2 · recruiting
NCT07525817 — A Real-World Study of Pirtobrutinib in cBTKi-Resistant/Intolerant Mature B-Cell Lymphoma · not yet recruiting
NCT05821192 — Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma. · NA · unknown
NCT04661943 — Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05834751 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ou Bai, MD/PHD
Last refreshed: 28 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05834751.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing